Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.35 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10302116 | 0.98 | CNR2 (0.39) | CNR2CRBNOPRL1CNR1ACACB | |
| SCHEMBL12889592 | 0.97 | CNR2 (0.41) | CNR2CRBNOPRL1CNR1 | |
| SCHEMBL10302118 | 0.97 | CNR2 (0.41) | CNR2CRBNOPRL1CNR1 | |
| SCHEMBL10302119 | 0.97 | CNR2 (0.41) | CNR2CRBNOPRL1CNR1 | |
| SCHEMBL10302115 | 0.92 | OPRL1 (0.36) | OPRL1FFAR4FFAR1 | |
| SCHEMBL10302122 | 0.89 | OPRL1 (0.32) | OPRL1FFAR4FFAR1PPARD | |
| SCHEMBL14766313 | 0.89 | CNR2 (0.35) | CNR2CRBNOPRL1CNR1FFAR1 | |
| SCHEMBL12735033 | 0.89 | CNR2 (0.36) | CNR2CRBNOPRL1CNR1FFAR1 | |
| SCHEMBL14765775 | 0.88 | CNR2 (0.35) | CNR2CRBNOPRL1CNR1 | |
| SCHEMBL10302121 | 0.88 | OPRL1 (0.33) | OPRL1ACACBFFAR4FFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CNR2 2145/4885CRBN 1642/4885OPRL1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.